Bio Green Med Solution, Inc. (BGMS)
NASDAQ: BGMS · Real-Time Price · USD
0.960
-0.012 (-1.18%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Bio Green Med Solution Revenue
In the year 2025, Bio Green Med Solution had annual revenue of $747.00K with 1,637.21% growth. Bio Green Med Solution had revenue of $666.00K in the quarter ending December 31, 2025.
Revenue (ttm)
$747.00K
Revenue Growth
+1,637.21%
P/S Ratio
7.09
Revenue / Employee
$62,250
Employees
12
Market Cap
5.30M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 11.51M |
| Moolec Science | 7.83M |
| PMGC Holdings | 590.08K |
| BioRestorative Therapies | 359.70K |
| Cardio Diagnostics Holdings | 14.83K |
| Pulmatrix | 3.00K |
| Ernexa Therapeutics | 1,000.00 |
BGMS News
- 4 weeks ago - BIO GREEN MED SOLUTION REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE - GlobeNewsWire
- 5 months ago - Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 9 months ago - Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 9 months ago - CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB - GlobeNewsWire
- 10 months ago - Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday? - Benzinga
- 10 months ago - CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER - GlobeNewsWire
- 10 months ago - CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT - GlobeNewsWire
- 10 months ago - Cyclacel Pharmaceuticals Announces Stock Split - GlobeNewsWire